Evaluation of Candida bloodstream infection and antifungal utilization in a tertiary care hospital

Abstract Background Candida bloodstream infections carry a significant mortality risk, justifying the importance of adequate antifungal therapy. This study describes trends in antifungal consumption using the Defined Daily Dose (DDD) and Days of Therapy (DOT) metrics, identifies the microbiological...

Full description

Bibliographic Details
Main Authors: Tatiana Aporta Marins, Alexandre R. Marra, Michael B. Edmond, Marines Dalla Valle Martino, Paula Kiyomi Onaga Yokota, Ana Carolina Cintra Nunes Mafra, Marcelino Souza Durão Junior
Format: Article
Language:English
Published: BMC 2018-04-01
Series:BMC Infectious Diseases
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12879-018-3094-9
_version_ 1818340193998995456
author Tatiana Aporta Marins
Alexandre R. Marra
Michael B. Edmond
Marines Dalla Valle Martino
Paula Kiyomi Onaga Yokota
Ana Carolina Cintra Nunes Mafra
Marcelino Souza Durão Junior
author_facet Tatiana Aporta Marins
Alexandre R. Marra
Michael B. Edmond
Marines Dalla Valle Martino
Paula Kiyomi Onaga Yokota
Ana Carolina Cintra Nunes Mafra
Marcelino Souza Durão Junior
author_sort Tatiana Aporta Marins
collection DOAJ
description Abstract Background Candida bloodstream infections carry a significant mortality risk, justifying the importance of adequate antifungal therapy. This study describes trends in antifungal consumption using the Defined Daily Dose (DDD) and Days of Therapy (DOT) metrics, identifies the microbiological profile, the time to initiation of empirical therapy, the adjustment after positive blood culture results for Candida, and the impact on in-hospital mortality rate in patients with candidemia. Methods An analysis of antifungal consumption from 2008 to 2016, and of candidemia cases from 2012 to 2016 was carried out in a private tertiary hospital. Results A total of 11,273 admissions were identified with a prescription for at least one type of antifungal therapy. Fluconazole was the most prescribed antifungal drug in terms of general consumption. Through the DDD and DOT metrics, we observed that over time, there was an increase in the consumption of liposomal amphotericin B, micafungin and voriconazole. Candida albicans was the most isolated species in blood cultures. Regarding candidemia, we analyzed samples from 115 patients. Empirical therapy was started within 24 h of blood culture in 44.3% of the cases, and in 81.7% of the cases, the antifungal was deemed to be adequate based in antifungal susceptibility testing, both of which were not associated with the in-hospital mortality rate. Conclusions Our study reinforces the importance of monitoring the consumption of antifungal agents, which helps in proposing actions that lead to their rational use and, consequently, reduces the appearance of resistant strains.
first_indexed 2024-12-13T15:39:01Z
format Article
id doaj.art-c049c0be83604972a7bf35e364ccff00
institution Directory Open Access Journal
issn 1471-2334
language English
last_indexed 2024-12-13T15:39:01Z
publishDate 2018-04-01
publisher BMC
record_format Article
series BMC Infectious Diseases
spelling doaj.art-c049c0be83604972a7bf35e364ccff002022-12-21T23:39:53ZengBMCBMC Infectious Diseases1471-23342018-04-0118111310.1186/s12879-018-3094-9Evaluation of Candida bloodstream infection and antifungal utilization in a tertiary care hospitalTatiana Aporta Marins0Alexandre R. Marra1Michael B. Edmond2Marines Dalla Valle Martino3Paula Kiyomi Onaga Yokota4Ana Carolina Cintra Nunes Mafra5Marcelino Souza Durão Junior6Hospital Israelita Albert EinsteinDivision of Medical Practice, Hospital Israelita Albert EinsteinOffice of Clinical Quality, Safety and Performance Improvement, University of Iowa Hospitals and ClinicsClinical Laboratory, Hospital Israelita Albert EinsteinDivision of Medical Practice, Hospital Israelita Albert EinsteinInstituto Israelita de Ensino e Pesquisa Albert Einstein, Hospital Israelita Albert EinsteinDivision of Medical Practice, Hospital Israelita Albert EinsteinAbstract Background Candida bloodstream infections carry a significant mortality risk, justifying the importance of adequate antifungal therapy. This study describes trends in antifungal consumption using the Defined Daily Dose (DDD) and Days of Therapy (DOT) metrics, identifies the microbiological profile, the time to initiation of empirical therapy, the adjustment after positive blood culture results for Candida, and the impact on in-hospital mortality rate in patients with candidemia. Methods An analysis of antifungal consumption from 2008 to 2016, and of candidemia cases from 2012 to 2016 was carried out in a private tertiary hospital. Results A total of 11,273 admissions were identified with a prescription for at least one type of antifungal therapy. Fluconazole was the most prescribed antifungal drug in terms of general consumption. Through the DDD and DOT metrics, we observed that over time, there was an increase in the consumption of liposomal amphotericin B, micafungin and voriconazole. Candida albicans was the most isolated species in blood cultures. Regarding candidemia, we analyzed samples from 115 patients. Empirical therapy was started within 24 h of blood culture in 44.3% of the cases, and in 81.7% of the cases, the antifungal was deemed to be adequate based in antifungal susceptibility testing, both of which were not associated with the in-hospital mortality rate. Conclusions Our study reinforces the importance of monitoring the consumption of antifungal agents, which helps in proposing actions that lead to their rational use and, consequently, reduces the appearance of resistant strains.http://link.springer.com/article/10.1186/s12879-018-3094-9AntifungalCandidemiaConsumptionDefined daily doseDays of therapy
spellingShingle Tatiana Aporta Marins
Alexandre R. Marra
Michael B. Edmond
Marines Dalla Valle Martino
Paula Kiyomi Onaga Yokota
Ana Carolina Cintra Nunes Mafra
Marcelino Souza Durão Junior
Evaluation of Candida bloodstream infection and antifungal utilization in a tertiary care hospital
BMC Infectious Diseases
Antifungal
Candidemia
Consumption
Defined daily dose
Days of therapy
title Evaluation of Candida bloodstream infection and antifungal utilization in a tertiary care hospital
title_full Evaluation of Candida bloodstream infection and antifungal utilization in a tertiary care hospital
title_fullStr Evaluation of Candida bloodstream infection and antifungal utilization in a tertiary care hospital
title_full_unstemmed Evaluation of Candida bloodstream infection and antifungal utilization in a tertiary care hospital
title_short Evaluation of Candida bloodstream infection and antifungal utilization in a tertiary care hospital
title_sort evaluation of candida bloodstream infection and antifungal utilization in a tertiary care hospital
topic Antifungal
Candidemia
Consumption
Defined daily dose
Days of therapy
url http://link.springer.com/article/10.1186/s12879-018-3094-9
work_keys_str_mv AT tatianaaportamarins evaluationofcandidabloodstreaminfectionandantifungalutilizationinatertiarycarehospital
AT alexandrermarra evaluationofcandidabloodstreaminfectionandantifungalutilizationinatertiarycarehospital
AT michaelbedmond evaluationofcandidabloodstreaminfectionandantifungalutilizationinatertiarycarehospital
AT marinesdallavallemartino evaluationofcandidabloodstreaminfectionandantifungalutilizationinatertiarycarehospital
AT paulakiyomionagayokota evaluationofcandidabloodstreaminfectionandantifungalutilizationinatertiarycarehospital
AT anacarolinacintranunesmafra evaluationofcandidabloodstreaminfectionandantifungalutilizationinatertiarycarehospital
AT marcelinosouzaduraojunior evaluationofcandidabloodstreaminfectionandantifungalutilizationinatertiarycarehospital